Clinical trial · Interventional
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
Breast Cancer Survivors: Exercise and Raloxifene
NCT00031811CI-TRIAL-00007001completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Raloxifene and exercise may improve bone health and quality of life in breast cancer survivors. Assessing bone health and quality of life may improve the ability to plan treatment. PURPOSE: Randomized clinical trial to study the effectiveness of raloxifene with or without exercise compared with exercise alone in women who have been previously treated for breast cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Menopausal Symptoms | — | UNRESOLVED | — |
| Osteoporosis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| quality-of-life assessment | Procedure | — | UNRESOLVED |
| raloxifene | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed breast cancer * No metastatic disease * At least 3 months but no more than 1 year since prior chemotherapy regimen including doxorubicin or methotrexate and catabolic steroids (to prevent nausea, vomiting, fluid retention, or hypersensitivity reactions) * No routine of regular strenuous exercise (more than 90 minutes per day 6 days/week OR 120 minutes per day 4 days/week) * Hormone receptor status: * Estrogen and progesterone receptor negative OR * Estrogen and progesterone receptor positive PATIENT CHARACTERISTICS: Age: * Any age Sex: * Female Menopausal status: * Postmenopausal (at diagnosis OR chemotherapy-induced) * No spontaneous menses for more than 6 months with increased follicle-stimulating hormone and decreased estradiol Performance status: * Ambulatory Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Cardiovascular: * No cardiac problems that would preclude exercise * No unstable angina Pulmonary: * No respiratory problems that would preclude exercise * No chronic obstructive pulmonary disease * No oxygen dependence Other: * No endocrine disease (e.g., parathyroid hormone disorders) that would accelerate bone turnover and loss * No musculoskeletal problems or other disease that would preclude exercise (e.g., movement-limiting arthritis, muscular dystrophy, or chronic fatigue syndrome) * No known cognitive or psychiatric disorders that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Disease Characteristics * Prior adjuvant or neoadjuvant chemotherapy allowed * No concurrent chemotherapy Endocrine therapy: * See Disease Characteristics * No concurrent tamoxifen Radiotherapy: * Prior adjuvant radiotherapy after chemotherapy allowed * No concurrent radiotherapy Surgery: * Not specified Other: * No concurrent bisphosphonates
References
Publications (0)
Data not yet available
No reference posted for this study.